According to Reuters, a federal judge has rejected Pfizer’s bid to escape an antitrust lawsuit accusing it of conspiring with India’s Ranbaxy Laboratories to delay sales of generic versions of its cholesterol drug Lipitor.
US District Judge Peter Sheridan in Trenton, New Jersey, on Tuesday, August 21, rejected arguments by Pfizer that the state-law antitrust claims insurers and others who purchased Lipitor have made are preempted by federal patent law.
Buyers of each drug claimed that the drug companies conspired to delay marketing generic versions with an illegal settlement agreement. They also said the drugmakers engaged in various unfair practices before the US Patent Office and the Food and Drug Administration.
The district court had dismissed the plaintiffs’ claims in opinions that were among the first discussing how to apply the Supreme Court’s 2013 decision that patent settlements can be antitrust violations in FTC v. Actavis.
According to Reuters, the appeals court’s reversal means that essentially all claims in two consolidated cases, from multiple plaintiffs, are back on the table, in some cases years after the lower court dismissed them. The appeals court held that the plaintiffs’ claims are plausible enough to proceed through discovery. It also stated the lower court didn’t properly credit the plaintiffs’ allegations with the benefit of the doubt in deciding whether to allow them to proceed.
Full Content: Reuters, Bloomberg BNA
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
FCC Votes to Restore Net Neutrality Rules
Apr 25, 2024 by
nhoch@pymnts.com
Apple Rejects Spotify’s Updated App Over In-App Pricing Disclosure
Apr 25, 2024 by
CPI
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI